Objectives. Chronic Pain Management. History of Pain. Definition of Pain 11/8/2016. Jill Duffy, ARNP. I have no disclosures to make.
|
|
- Shauna Murphy
- 5 years ago
- Views:
Transcription
1 Objectives 1. Describe the prescribing guidelines created by the CDC and the impact on treatment of pain. Chronic Pain Management Jill Duffy, ARNP 2. Explain the importance of establishing a clear diagnosis prior to prescribing opioids for chronic pain. 3. Describe the pain treatment ladder for patients with chronic pain. 4. Describe patient-provider shared responsibility while prescribing medications for chronic pain. 5. Describe the classes of medications that are utilized in the treatment of chronic pain. History of Pain I have no disclosures to make. Derived from Greek POINE goddess of revenge and Roman POENA spirit of punishment Definition of Pain An unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. (International Association for the Study of Pain, Merskey, 1986) Pain is whatever the experiencing person says it is, existing whenever he says it does. (McCaffery, 1968) CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016 Centers for Disease Control and Prevention Morbidity and Motality Weekly Report, March 15,
2 Guideline #1 DETERMINING WHEN TO INITIATE OR CONTINUE OPIOIDS FOR CHRONIC PAIN Nonpharmacological therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacological therapy and nonopioid pharmacologic therapy as appropriate. No drug should be prescribed for any disorder without weighing the risk versus benefit. Guideline #2 Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety. Sometimes the goal is comfort care and delayed dysfunction (Spinal cord injury, Parkinson s disease, etc.) Guideline #3 Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy. Guideline #4 When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/longacting (ER/LA) opioids. OPIOID SELECTION, DOSAGE, DURATION, FOLLOW-UP, AND DISCONTINUATION 2
3 Guideline #5 When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing dosage to > 50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to >90 MME/day or carefully justify a decision to titrate dosage to >90 MME/day. The daily dosing is important, but also individual There is no universally accepted MME Schatman M, Fudin J. The Myth of Morphine Equivalent Daily Dosage. Medscape May. Shaw K, Fudin J. Evaluation and Comparison of Online Equianalgesic Opioid Dose Conversion Calculators. Practical Pain Management August: 13(7):61-66 Rennick A, Atkinson T, Cimino, NM, Strassels, SA, McPherson ML, Fudin J. Variability in Opioid Equivalence Calculations. Pain Medicine 2016:17: Guideline #6 Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediaterelease opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days of less will often be sufficient; more than seven days will rarely be needed. Guideline #7 Clinicians should evaluate benefits and harms with patients within 1-4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids. Some times one opioid doesn t work or is not well tolerated, or both, and there may be another opioid that is a better option. ASSESSING RISK AND ADDRESSING HARMS OF OPIOID USE 3
4 Guideline #8 Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone wen factors that increase risk for opioid overdose, such as history of overdose, history of substance abuse disorder, higher opioid dosages (>50 MME/day), or concurrent benzodiazepine use, are present. Guideline #9 Clinicians should review the patient s history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every three months. Guideline #10 When prescribing opioids for chronic pain, clinicians should used urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs. Guideline #11 Clinicians should avoid prescribing opioid pain medications and benzodiazepines concurrently whenever possible. Alcohol Guideline #12 Approximately 20-30% of opioid related deaths involved alcohol. Alcohol may cause some ER/LA formulations to release the drug all at once. Combination of alcohol and single drug class in ER visits Opioid pain relievers, 26,446 (13.8%) Oxycodone/combinations: 10,160 Hydrocodone/combinations: 7,251 Benzodiazepines, 38,244 (34.1%) Alprazolam: 13,063 Clonazepam: 7,734 Combination of benzos, opioids, alcohol Of 3883 opioid related deaths, 860 (22.1%) involved alcohol Of 1512 benzo related deaths, 324 (21.4%) involved alcohol. Clinicians should offer or arrange evidencebased treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder. Jones C, Paulozzi LJ, Mack KA. Alcohol Involvement in Opioid Pain Reliever and Benzodiazepine Drug Abuse- Related Emergency Department Related Deaths United States, Morbidity and Mortality Weekly Report. October 10, 2014:63(40);
5 Types of Pain: Nocioceptive Pain that is related to an unpleasant stimulus or one that would be unpleasant if prolonged. Stubbing your toe Hand in ice water Somatic Originates in skin, muscles, bone, or soft tissue Closely aligned to type and extent of injury Visceral Activation of specialized fibers: organs and viscera Pain due to damaged or dysfunctional nerves Burning Stabbing Shooting Types of Pain: Neuropathic Peripheral neuropathy Central neuropathic pain Spinal cord injury Post-stroke pain Cancer Pain Tumor related Pain syndromes Treatment related Inflammatory Pain Chemical buildup of irritants Tissue damage Inflammation Other types of Pain Sympathetically Maintained Pain Abnormal connections between pain fibers and sympathetic nerve fibers Edema Temperature Blood flow regulation Pain Treatment Ladder Pain Treatment Ladder Interventional Pain NSAIDS OTC Medications Physical Therapy Manipulation TENS Muscle Relaxants Nerve Blocks Behavioral Programs Corrective Surgery Long Term Oral Opioids Implantable therapy spinal cord stimulation Implantable therapy interspinal drug infusion Neuroablation (chemical or surgical) 5
6 Surgery or injury causes inflammation Pain: Acute to Chronic Sensitization with sustained activation of the PNF Peripheral Nociceptive Fibers Activated Structural remodeling with CNS neuroplasticity and hyperactivty Transient Activation with sustained currents Central Sensitization Syndrome Multiple and complex mechanisms Temporal summation or windup Long-term potentiation Heterosynaptic potentiation Amplification from one set of nociceptive fibers to other sets not stimulated Dysfunctional descending pain inhibition Activations of descending facilitatory pathway Medications Acute pain can respond best to analgesic pharmacotherapy Chronic pain responds better to multimodal therapy Bony pain = NSAID with opioid Neuropathic pain = TCAs, anticonvulsants, local anesthetics, topical capsaicin, nerve blocks Infections damage = incision and drainage, anti-infectives GI spasm = anticholinergic agents Constipation = stimulating laxatives Lymphedema = physical therapy, compression Use of Every Medication is an EXPERIMENT Potential benefit outweighs the potential harm Consider initiation a trial to determine the outcome Continue only if benefits outweigh the risks Lessen adverse outcomes Set patient expectations about their therapy Cost to benefit issues considered by clinicians Patient Preference Inquire about patient belief and preferences Prior experience Other s response to opioids Misconceptions Medication does not cure pain Variability in response to analgesics Counsel on the need to adjust medication and dosing to optimize response Treat the Cause Misconception to increase the dose Until pain is relieved adequately Until unacceptable side effects Myofascial pain = physical therapy 6
7 Synergy and Potentiation Combinations can increase response with synergy and potentiation Bone pain = NSAID and opioid Neuropathic pain = tricyclic antidepressants or anticonvulsant medications with opioid Two drugs act together to produce enhanced action NSAID provides peripheral antiinflammatory activity Opioid acts largely centally One drug enhances the effect of the other Acetaminophen acts at the serotonergic system in the brain Analgesics Acetaminophen Caution above 2 grams/day Modulates COX-1, COX-2, COX-3 enzymes in the brain Impacts neurogenic inflammation or serotonergic mechanisms Can boost the endocannabinoid system No to NSAIDs NSAIDS Most widely prescribed medications in the world with over 2 dozen commercially available in the US Action Inhibit prostaglandin synthesis Analgesic, anti-inflammatory, antipyretic Caution Renal failure Hepatic disease Try at full dose for 3 weeks then rotate if no response Classes Salicylates Aspirin Choline magnesium trisaliclate (Trilisate, Tricosal) Diflunisal (Dolobid) Salsalate (Disalcid) Propionic Acid derivatives Fenoprofen (Nalfon Fluribiprofen (Ansaid) Ibuprofen (Advil, Motrin, others) Ketoprofen (Orudis) Naproxen (Naprosyn, others) Naproxen Sodium (Aleve, Anaprox) Oxaprozin (Daypro) Fenamates Diclofenac (Voltaren) Tolmetin (Tolectin) Ketoralac (Toradol) Mefanamic acid (Ponstel) Meclofenamate (Meclomen) Enolic acid derivatives (oxicams) Meloxicam (Mobic) Piroxicam (Feldene) Nabumetone (Relefen) Acetic acid derivatives Etodolac (Lodine) Indomethacin (Indocin) Sulindac (Clinoril) COX-2 selective NSAID (coxib) Celecoxib (Celebrex) 7
8 Skeletal Muscle Relaxants Sedative Carisoprodol (Soma) Chlorzoxazone (Parafon Forte) Metaxalone (Skelaxin) Methocaramal (Robaxin) TCA-like Cyclobenzaprine (Flexaril) Antihistamine Orphenadrine (Norflex) GABA-type Diazepam (Valium) Baclofen (Lioresal) Central Alpha-2 Agonist Tizanidine (Zanaflex) Antidepressants Selective Serotonin Receptor Inhibitors (SSRIs) Citalopram Escitalopram Fluoxetine Fluvoxamine Paroxetine HCL Paroxetine mesylate Sertraline Serotonin and norepinephrine reuptake inhibitors (SNRIs) Desvenlafaxine Duloxetine Venlafaxine Tricyclic Antidepressants (TCAs) Amitriptyline Clomipramine Desipramine Imipramine Maprotiline Nortriptyline Gabapentin Pregabalin Carbamazepine Oxcarbazepine Lamotrigine Other Valproic acid Sodium valproate Topiramate Levetiracetam Zonisamide Tiagabine Lacosamide Anticonvulsants Capsaicin Lidocaine Ketamine Topical Agents Opioids Opioids 8
9 Opioids Opioids Tramadol only opioid studied for use in fibromyalgia Positive effect on pain and improved quality of life Serotonin and norepinepherine effects Metabolized by CYP450 isoenzyme 2D6 Codeine 10% of population lack enzyme to convert to morphine (CYP450 isoenzyme 2D6) Ultra-metabolism may result in toxic effects Tapentadol (Nucynta) Noradrenergic receptor effects Metabolized via hepatic glucuronidation with less drug-drug interactions Buprenorphine Partial opioid agonist Indicated for moderate to severe pain in patients requiring a continuous, around the clock opioid analgesic for an extended period of time. Osteoarthritis, low back pain Schedule III Advantages Lower abuse potential Less dangerous in an overdose Causes fewer withdrawal symptoms Buprenorphine Patch Each patch is meant to be worn for 7 days Rotate sites: upper outer arm, upper chest, upper back or side of the chest Initial dose in opioid-naïve patients is always 5 mcg/hr Conversion typically less than 30 MME/day start with 5 mcg/hr and MME/day start with 10 mcg/hr. Buprenorphine Patch Available in the following strengths: 5 mcg/hr 7.5 mcg/hr 10 mcg/hr 15 mcg/hr 20 mcg/hr Do not increase for at least 72 hours Buprenorphine Film Buccal film Dosing every 12 hours Available in the following strengths: 75, 150, 300, 450, 600, 750, 900 mcg Opioid naïve start at 75 mcg daily or q12hr. Opioid tolerant Taper down opioid to 30 MME/day or less. 30 MME/day start 75 mcg daily or q12hr MME/day start 150 mcg q12hr MME/day start 300 mcg q12hr Max dose 900 mcg q12hr Increase dosing after 4 days by 150 mcg every 12 hours 9
10 Changing Opioids Lack of therapeutic response Development of adverse effects Change in patient status Other considerations Opioid/formulation availability Formulary issues Patient/family heath care beliefs Opioid rotation Explain the Change Improved pain management ER/LA show less troughs/valleys Enhanced adherence to opioid therapy Improved patient outcomes Better analgesic effects Better functional status Fewer adverse effects Opioid Conversion Process 1. Assess pain. 2. Determine the total daily dose of current opioid long acting and short acting 3. Decide which opioid analgesic with be used for the new agent. 4. Consult established conversion table to determine new dose. 5. Individualize dosage based on assessment information. 6. Patient follow-up and reassessment (7-14 days) Abuse-Deterrent Opioid Formulations Deter abuse by potential abusers 70% of illegal users obtain by stealing, purchasing illegally, or receiving from family or friends. Dump effect: acceleration associated with rapid high Higher peak over shorter time National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO) Track drugs of abuse Current popularity Preferred method of abuse Abuse Deterrent Opioids Add pharmaceutical or chemical component Deter ability to physically alter the drug s original form to extract the active ingredient Crushing, chewing, mixing with a solvent Examples Morphine + naltrexone in a sequestered core Oxycodone + hydrophophobic fatty and waxy materials = microspheres Oxymorphone ER with crush resistant properties Aversion technology = add niacin to oxcodone Moorman-Li, R; Motycka, CA; Inge, LD; Congdon, JM; Hobson, S; Pokropski, B. A Review of Abuse- Deterrent Opioids for Chronic Nonmalignant Pain. Pharmacy and Therapeutics, 2012 July 37(7); MAKING IT WORK 10
11 The 15-Minute Office Visit At Each Visit Acute: Identify, diagnose with examination, treat, improvement Chronic: Complete resolution is not likely Ask What do you think I can do to help your pain? Ask about pain and record the level Determine the functional status and if treatment is improving function Modify treatment according to response Use non-pharmacological and pharmacological methods for pain control Explain the available options and foster a positive attitude in the patient toward dealing with the pain Bonica s Management of Pain Streamlining the Visit Assessment Tools Substance Abuse Screening The Screener and Opioid Assessment for Patients with Pain (SOAPP) Opioid Risk Tool (ORT) Goal Setting and Plan of Action Symptom management Functional improvement The 4 As of Treatment Sucess Analgesia or pain score Activities of daily living or functional outcome that is meaningful to patient Adverse events Aberrant behavior Thank you. Any questions? 11
Knock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationAvailable Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Non-Opioids LAST REVIEW 5/9/2017 THERAPEUTIC CLASS Pain REVIEW HISTORY 2/16, 5/15 LOB AFFECTED Medi-Cal (MONTH/YEAR) This
More informationNSAIDs. NSAIDs are important but they can have side effects.
NSAIDs Pain Treatment Nonsteroidal anti-inflammatory drugs (NSAIDs) are often recommended for initial treatment of pain and can be added to more powerful drugs to treat worse pain. Acetaminophen, such
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationPrescribing drugs of dependence in general practice, Part C
HO O Prescribing drugs of dependence in general practice, Part C Key recommendations and practice points for management of pain with opioid therapy H H HO N CH3 Acute pain Acute pain is an unpleasant sensory
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationFull details and resource documents available:
Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,
More informationused for dealing with anxiety. Both of the drugs are also given to patients for dealing with pain activated by damaged or hypersensitive nerves that i
Aspirin (also classified under NSAIDs or acetylsalicylic acid). Morphine and morphine sustained release (MS-Contin, Avinza, Kadian) Oxymorphone (Opana, Opana ER) Hydrocodone with acetaminophen (Lortab
More informationAmber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center
Pharmacologic Management of Pain Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center Objectives Identify types of
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationNew Guidelines for Prescribing Opioids for Chronic Pain
New Guidelines for Prescribing Opioids for Chronic Pain Andrew Lowe, Pharm.D. CAPA Meeting October 6, 2016 THE EPIDEMIC Chronic Pain and Prescription Opioids 11% of Americans experience daily (chronic)
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationPharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND
Pharmacotherapy of Pain SUPHAT SUBONGKOT, PHARM.D. BCOP, BCOP CLINICAL PHARMACY DIVISION KHON KAEN UNIVERSITY, THAILAND Therapeutic Strategies for Pain and Disability Pharmacotherapy Rehabilitative approaches
More informationI. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more
NSAID steroid update Leo Semes, OD, FAAO I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more II. Topical NSAIDS ophthalmic application III. Oral NSAIDs a. Precautions
More informationDisclosures. Management of Chronic, Non- Terminal Pain. Learning Objectives. Outline. Drug Schedules. Applicable State Laws
Disclosures Management of Chronic, Non- Terminal Pain No financial disclosures or conflicts of interest to report Michael A. Smith, PharmD, BCPS Clinical Assistant Professor, University of Michigan College
More informationCurrent Pharmacotherapy of Chronic Pain
S16 Journal of Pain and Symptom Management Vol. 19 No. 1(Suppl.) January 2000 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia Current Pharmacotherapy of Chronic Pain Russell
More informationAvailable Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Fibromyalgia P&T DATE: 5/9/2017 CLASS: Pain Management REVIEW HISTORY 9/15, 5/14, 11/12, 9/12, LOB: Medi-Cal (MONTH/YEAR)
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationPrescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD
Prescribing Opioids in the Opioid Epidemic Scott Woffinden, PA-C Jason Chapman, JD What's the Problem? http://www.zdoggmd.com/blank-script-taylor-swift-parody/ What's the Problem? CDC 115 Americans die
More informationPractical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014
Practical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014 Overview Types of Pain Physical Examination of Pain Pharmacologic Approach in Pain Management
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More information: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
More informationPharmacological treatment of Pain
Pharmacological treatment of Pain None Disclosures and Conflict of Interest Dr John F. Flannery Medical Director MSK and Multisystem Rehab Program PMR - FRCPC Objectives At the end of this presentation
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain* PROVIDER REFERENCE CARDS Low Back Pain.
VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain* PROVIDER REFERECE CARDS Low Back Pain (Update 2007) L B P *Developed by the American College of Physicians and the American
More informationSummary of Recommendations...3. PEG: A Three-Item Scale Assessing Pain (Appendix A) Chronic Pain Flow Sheet Acute Pain Flow Sheet...
Table of Contents Summary of Recommendations....3 PEG: A Three-Item Scale Assessing Pain (Appendix A)...12 Chronic Pain Flow Sheet...13 Acute Pain Flow Sheet...14 Pocket Guide: Tapering Opioids for Chronic
More informationTapering Injured Workers off Prescription Drugs
www.prium.com Tapering Injured Workers off Prescription Drugs Learning Objectives 1. Define polypharmacy complexities 2. Explain the biopsychosocial model 3. Outline the weaning process 4. Examine real
More informationRational Polypharmacy
Rational Polypharmacy Thomas B. Gregory, PharmD, BCPS, CPE, FASPE Disclosures Clinical advisory board: Daiichi Sankyo 1 Introduction Cox Health Ambulatory Pain Clinic Pharmacy Specialist Learning Objectives
More informationNo Pain, No Gain Pharmacy Patient Pain Counseling Competition
No Pain, No Gain Pharmacy Patient Pain Counseling Competition Offered by the Maine Pharmacy Association as part of the 2010 MPA Fall Conference Sponsored by an educational grant by NASPA and Purdue Pharma,
More informationAcetaminophen and NSAIDS. James Moriarity MD University of Notre Dame
Acetaminophen and NSAIDS James Moriarity MD University of Notre Dame Lecture Goals Understand the indications for acetaminophen and NSAID use in musculoskeletal medicine Understand the role of Eicosanoids
More information9/30/2017. Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management. Program Objectives. Impact of Poorly Managed Pain
Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management MARY BETH PARTYKA MSN ADULT NURSE PRACTITIONER ADVOCATE CHRIST MEDICAL CENTER ADULT PAIN SERVICE Program Objectives Identify
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationMUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed
MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More information3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo
Adjuvant pain medications in geriatrics Thomas B. Gregory, Pharm.D., BCPS, CPE, FASPE Clinical Pharmacy Specialist Pain Management CoxHealth Springfield, MO Disclosures Clinical advisory board member-
More informationScope of the Opiate Problem 6/5/18. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond. Overview.
Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond David Anisman, MD Medical Director, Farmington Health Center (Primary Care) Associate Medical Director, Community
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationTHE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING
THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING Ernest J Dole, PharmD, PhC, FASHP, BCPS Clinical Pharmacist University of New Mexico Hospitals And Clinical Associate Professor University
More informationFighting the Good Fight: How to Convert Opioids Just Right!
Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,
More informationNociceptive Pain. Pathophysiologic Pain. Types of Pain. At Presentation. At Presentation. Nonpharmacologic Therapy. Modulation
Learning Objectives Effective, Safe Analgesia An Approach to Appropriate Outpatient Chronic Pain Treatment By the end of this presentation, participants will be able to: Identify multiple factors that
More informationRational Polypharmacy in Pain Management
Rational Polypharmacy in Pain Management Charles Argoff, MD Disclosures: Charles Argoff Financial Disclosure: Consultant: Teva, Daiichi Sakyo, Pfizer, Nektar, Purdue, Depomed, Arbor, Novartis, Quest, Gruenenthal,
More informationCynthia B. Jones, Director Department of Medical Assistance Services (DMAS)
Department of Medical Assistance Services 600 East Broad Street, Suite 1300 Richmond, Virginia 23219 MEDICAID MEMO http://www.dmas.state.va.us TO: All Prescribing Providers, Pharmacists, and Managed Care
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationMedications for Persistent Pain
Medications for Persistent Pain An Older Adult s Guide to Safe Use of Pain Medications THE AGS FOUNDATION FOR HEALTH IN AGING What is persistent pain? Introduction Persistent, or chronic pain, is pain
More informationDescribe Identify Compare Recognize
Goal To educate nurses about the challenges associated with treating chronic pain and the safety and efficacy of alternative therapy options in relation to Opioids. Objectives Describe the challenges associated
More informationPain Management and Opioid Treatment Services
Pain Management and Opioid Treatment Services Davis, CA (530) 753-4300; Voice mail: (916) 715-5856 davidmeelee@gmail.com www.changecompanies.net www.trainforchange.net www.tipsntopics.com www.asamcriteria.org
More informationNon Opioid Approaches to Pain and Musculoskeletal Disorders KEVIN ODONNELL, DO FLAGSTAFF BONE AND JOINT
Non Opioid Approaches to Pain and Musculoskeletal Disorders KEVIN ODONNELL, DO FLAGSTAFF BONE AND JOINT Learning Objectives Review Opioid Crisis CDC Guidelines for opioid prescribing Discuss Alternatives
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: potassium (Zipsor), (Zorvolex) Reference Number: CP.CPA.280 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end
More informationDisclosures. Objectives 9/8/2015
The Aftermath of the Decade of Pain: Alternatives to Opioids in Chronic Pain Management Julie Cunningham, PharmD, BCPP Disclosures No relevant financial disclosures I will discuss off-label uses of antiepileptics,
More informationA Patient s Guide to The Medication Approach to Chronic Pain
A Patient s Guide to The Medication Approach to Chronic Pain 651 Old Country Road Plainview, NY 11803 Phone: 5166818822 Fax: 5166813332 p.lettieri@aol.com DISCLAIMER: The information in this booklet is
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationin this web service Cambridge University Press
Prescriber's Guide in this web service in this web service Essential Pain Pharmacology The Prescriber's Guide Howard S. Smith Professor of Anesthesiology, Internal Medicine, Physical Medicine and Rehabilitation,
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationCancer patients at End-of-Life: Multidimensional Pain Requiring Multimodal Therapy
Cancer patients at End-of-Life: Multidimensional Pain Requiring Multimodal Therapy Presented by: Marsha Farrell BSN, RN-BC, CHPN Pathways to Success Conference by the Bay November 12, 2014 Conflict of
More informationLong-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018
Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting
More informationPRIUM Educational Services Managing Drugs & Chronic Pain in Work Comp
PRIUM Educational Services Managing Drugs & Chronic Pain in Work Comp Your Speaker Mark Pew, Senior Vice President of Product Development PRIUM (www.prium.net) Medical Intervention on Clinically Complex
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationNeuropathic Pain and Pain Management Options. Mihnea Dumitrescu, MD
Neuropathic Pain and Pain Management Options Mihnea Dumitrescu, MD www.austinppc.com International Association for the Study of Pain (IASP): Definition of Pain Pain is an unpleasant sensory and emotional
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationB. Long-acting/Extended-release Opioids
4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More information21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content
Volume of Prescribing by Dentists 2011 ( a reminder) BASHD Therapeutics Analgesics and Pain Management Analgesics account for 1 in 80 dental prescriptions made A lot more analgesics will be suggested for
More informationSAFE PRESCRIBING: RULES AND REGULATIONS. Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017
SAFE PRESCRIBING: RULES AND REGULATIONS Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017 DISCLOSURES I have no financial disclosures. OBJECTIVES Discuss the significance of the opiate
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationINITIAL COMPREHENSIVE PAIN QUESTIONNAIRE
INITIAL COMPREHENSIVE PAIN QUESTIONNAIRE Name: DOB: Address: Phone number: Referring Physician name: PAIN HISTORY: Was the pain a result of a particular incident (injury, accident, illness): No Yes (please
More informationMonte H. Moore, MD. Idaho Physical Medicine and Rehabilitation. Meridian, ID
Monte H. Moore, MD Idaho Physical Medicine and Rehabilitation Meridian, ID Chronic pain brief review Opiates important things to know Factors in determining whether to use an opiate What to watch for if
More informationPharmacologic Management of Pain
Pharmacologic Management of Pain Natalie Keil, Pharm.D. NMCSD PGY1 Pharmacy Practice Resident Palliative Care Nursing Symposium October 14, 2011 The views expressed in this presentation are those of the
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2099-5 Program Prior Authorization/Medical Necessity Buprenorphine Products (Pain Indications) Medication Belbuca (buprenorphine
More informationRe: Draft Guideline for the Use of Opioids for Chronic Pain (Docket No. CDC )
January 13, 2016 Veronica Kennedy Acting Executive Secretary, Centers for Disease Control and Prevention National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770
More informationOpioid Use: Current Challenges & Clinical Advancements
Opioid Use: Current Challenges & Clinical Advancements Whitney Bergquist, PharmD, MBA, BCPS Acute Care NPPA Conference February 8, 2017 2017 MFMER slide-1 No Disclosures 2017 MFMER slide-2 Objectives Summarize
More informationLearning Objectives. Perioperative goals. Acute Pain in the Chronic Pain Patient for Ambulatory Surgery 9/8/16
Acute Pain in the Chronic Pain Patient for Ambulatory Surgery Danielle Ludwin, MD Associate Professor of Anesthesiology Division of Regional and Orthopedic Anesthesia Columbia University Medical Center
More informationPAIN. (Review article for physicians) Method of Alexander Mauskop, MD New York Headache Center, New York, NY. From Connâs Current Therapy, 1996
PAIN (Review article for physicians) Method of Alexander Mauskop, MD New York Headache Center, New York, NY. From Connâs Current Therapy, 1996 PHARMACOTHERAPY Major advances are being made in the development
More informationMitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly
Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly Mary Lynn McPherson, PharmD, MDE, MA, BCPS, CPE Professor and Executive Director, Advanced Post-Graduate
More informationALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal
ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12
More informationDiagnosis (Please be specific & provide as much information as possible):
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationManaging Pain after Transplant Denice Economou, RN,MN,CHPN,AOCN
Managing Pain after Transplant Denice Economou, RN,MN,CHPN,AOCN Oncology Clinical Nurse Specialist, Senior Research Specialist City of Hope Definition of Pain Pain is an unpleasant sensory and emotional
More informationFDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes
FDA strengthens warning that non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) can cause heart attacks or strokes Safety Announcement [7-9-2015] The U.S. Food and Drug Administration (FDA) is strengthening
More informationPain control in Cancer patients. Dr Ali Shoeibi, Assistant Professor of Neurology
Pain control in Cancer patients Dr Ali Shoeibi, Assistant Professor of Neurology More than two thirds of patients with advanced cancer experience cancer pain Almost all pain can be controlled to some extent
More informationSkeletal Muscle Relaxants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: June 1, 2016 Renewal Date: August 16, 2017 Skeletal Muscle Relaxants Drug Class Prior Authorization Protocol This policy has been developed through review of
More informationRisk Reduction Strategies in Pain Management
Risk Reduction Strategies in Pain Management Melissa J. Durham, PharmD, MACM, BCACP, DAAPM Assistant Professor of Clinical Pharmacy USC School of Pharmacy Clinical Pharmacist, The USC Pain Center Learning
More informationRecommendations in Opioid Prescribing Guidelines for Chronic Pain
Recommendations in Opioid Prescribing Guidelines for Chronic Pain The use of opioids for treating chronic pain has been increasing. 1 In 2010, an estimated 20% of patients presenting to physician offices
More informationAppendix D: Drug Tables
Appendix D: Drug Tables A. Short-acting, Orally Administered Opioids Table D-1: Use of Short-acting, Orally Administered Opioids in Adults [198] Additional Maximum APAP dose: 4000 mg/d (2000 mg/d in chronic
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More informationA Patient s Guide to Pain Management Medications
A Patient s Guide to Pain Management Medications 228 West Main, Suite C Missoula, MT 59802 Phone: info@spineuniversity.com DISCLAIMER: The information in this booklet is compiled from a variety of sources.
More informationOptimizing Neuropathic Pain Medications. Dermot More-O Ferrall, MD
Optimizing Neuropathic Pain Medications Dermot More-O Ferrall, MD PAIN MANAGEMENT OPIOID DISPENSING Objectives Understand: Definition and subtypes of pain Pathophysiology of neuropathic pain Pharmacologic
More informationAcute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX
Acute Pain Management in the Hospital Setting Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX 2 What is Pain? An unpleasant sensory and emotional experience associated
More informationYou May Be at Risk. You are currently taking a non-steroidal anti-inflammatory drug (NSAID):
NSAIDS You May Be at Risk You are currently taking a non-steroidal anti-inflammatory drug (NSAID): Aspirin Diclofenac (Voltaren ) Diflunisal (Dolobid ) Etodolac (Lodine ) Ibuprofen (Advil ) Ketoprofen
More informationClinical and Contextual Evidence Reviews
Clinical and Contextual Evidence Reviews Roger Chou, MD Professor of Medicine Oregon Health & Science University Director, Pacific Northwest Evidence-based Practice Center Purpose Summarize methods for
More information